Financials

	2022	2023
Net sales	4.85Cr 4.25Cr 4.02Cr 3.66Cr 6.85Cr 464.48Cr 6.9Cr 48Cr 19Cr 237.29Cr 18Cr 18Cr 762.64Cr	4.92Cr 4.31Cr 4.07Cr 3.71Cr 6.95Cr 471.21Cr 7Cr 49Cr 19Cr 240.73Cr 18Cr 18Cr 773.68Cr
Net income	-2.86Cr -2.51Cr -2.37Cr -2.16Cr -4.05Cr -274.44Cr -4.08Cr -28Cr -11Cr -140.21Cr -11Cr -11Cr -450.61Cr	-2.06Cr -1.81Cr -1.71Cr -1.56Cr -2.92Cr -197.75Cr -2.94Cr -20Cr -7.93Cr -101.02Cr -7.75Cr -7.58Cr -324.68Cr
Net Debt	1.15Cr 1.01Cr 95.37L 86.91L 1.63Cr 110.29Cr 1.64Cr 11Cr 4.42Cr 56Cr 4.32Cr 4.23Cr 181.08Cr	91.41L 80.21L 75.76L 69.04L 1.29Cr 88Cr 1.3Cr 9.07Cr 3.51Cr 45Cr 3.43Cr 3.36Cr 143.85Cr

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

Sector

27/25/27	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/25/19	EnVVeno Medical Names Jennifer Bright CFO	MT
05/25/05	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/25/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/25/21	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/25/18	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/25/14	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/25/29	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/25/14	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/25/13	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/25/08	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/24/23	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/24/15	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/24/01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/23/31	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/23/20	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/22/20	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/25/14	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/24/08	Biolase: Q3 Earnings Snapshot	AQ
08/24/08	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
02/24/02	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
09/24/09	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Martha Somerman BRD	Director/Board Member	-	16/08/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE INC	-6.39%	-2.55%	-	-	36
CHURCHILL CAPITAL CORP XI	+1.64%	-3.64%	-	-	69Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	-0.10%	-	-	65Cr
BAIN CAPITAL GSS INVESTMENT CORP.	+0.19%	+0.19%	-	-	60Cr
CHURCHILL CAPITAL CORP XII	+0.65%	+1.36%	-	-	60Cr
CANTOR EQUITY PARTNERS IV, INC.	+0.15%	-0.39%	+1.28%	-	59Cr
CENTIEL AG	+0.68%	-6.29%	+279.62%	-73.63%	59Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.27%	+0.45%	+11.60%	-	55Cr
NEW AMERICA ACQUISITION I CORP.	0.00%	-0.10%	-	-	50Cr
Average	-0.36%	-1.07%	+97.50%	-73.63%	59.62Cr
Weighted average by Cap.	+0.43%	-1.13%	+99.13%	-73.63%